Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 11/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GGT1 | P19440 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742767 | 0.83 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19788058 | 0.83 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22001982 | 0.80 | TGFBR1 (0.50) | FOLH1NAALAD2RIMKLAMAPTGGT1 | |
| SCHEMBL17615103 | 0.80 | FPR2 (0.44) | FPR2FOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL19788064 | 0.80 | FOLH1 (0.49) | FPR2FOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL18253627 | 0.80 | FOLH1 (0.49) | FPR2FOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL8760408 | 0.80 | SIRT6 (0.57) | FOLH1SMN1; SMN2SLC6A5EPHX1 | |
| SCHEMBL19360075 | 0.79 | FOLH1 (0.44) | FOLH1NAALAD2RIMKLAMAPTGGT1 | |
| SCHEMBL23835515 | 0.79 | SIRT6 (0.63) | FOLH1SMN1; SMN2SLC6A5EPHX1 | |
| SCHEMBL2863617 | 0.79 | SIRT6 (0.63) | FOLH1SMN1; SMN2SLC6A5EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | FPR2 3893/4885FOLH1 135/4885NAALAD2 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.